JOHN DARAMOLA: Open Payments
NPI 1013995810 · CLEBURNE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$402 in 14 payments from 7 companies in 2025. Trend: 2023 $134 · 2024 $361 · 2025 $402
Food & beverage: $402
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $173 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $72 |
| E.R. Squibb & Sons, L.L.C. | 2 | $45 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $39 |
| ABBVIE INC. | 2 | $37 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19 |
| Novo Nordisk Inc | 1 | $17 |
Products named: BREZTRI, Kerendia, FARXIGA, ELIQUIS, CAPLYTA, VRAYLAR, JARDIANCE, Ozempic.
Industry payments across TX — which companies pay providers there.
